Hector L. Franco

Dr. Hector L. Franco

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2021 in Molecular Cell
Verified
Journal Article
Closed access
MRMatthew J. Regner
Matthew J. Regner
KWKamila Wisniewska
Kamila Wisniewska
SGSusana Garcia-Recio
Susana Garcia-Recio
ATAatish Thennavan
Aatish Thennavan
RMRaul Mendez-Giraldez
Raul Mendez-Giraldez
HFHector L. Franco
Hector L. Franco

8 October 2010 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
HFHector L. Franco
Hector L. Franco
JCJosé Casasnovas
José Casasnovas
JRJosé R. Rodríguez-Medina
José R. Rodríguez-Medina
CCCarmen Cadilla
Carmen Cadilla
Twist1 and Twist2 are highly conserved members of the Twist subfamily of bHLH proteins responsible for the transcriptional regulation of the developmental programs in mesenchymal cell lineages. The regulation of such processes requires that Twist1 and Twist2 function as molecular switches to activate and repress target genes by employing several direct and indirect mechanisms. Modes of action by these proteins include direct DNA binding to conserved E-box sequences and recruitment of coactivators or repressors, sequestration of E-protein modulators, and interruption of proper activator/repressor function through protein–protein interactions. Regulatory outcomes of Twist1 and Twist2 are themselves controlled by spatial-temporal expression, phosphoregulation, dimer choice and cellular localization. Although these two proteins are highly conserved and exhibit similar functions in vitro, emerging literature have demonstrated different roles in vivo. The involvement of Twist1 and Twist2 in a broad spectrum of regulatory pathways highlights the importance of understanding their roles in normal development, homeostasis and disease. Here we focus on the mechanistic models of transcriptional regulation and summarize the similarities and differences between Twist1 and Twist2 in the context of myogenesis, osteogenesis, immune system development and cancer.

22 December 2017 in Genome Research
Verified
Journal Article
Open access
PDF file
HFHector L. Franco
Hector L. Franco
ANAnusha Nagari
Anusha Nagari
VMVenkat S. Malladi
Venkat S. Malladi
WLWenqian Li
Wenqian Li
YXYuanxin Xi
Yuanxin Xi
WKW. Lee Kraus
W. Lee Kraus
Noncoding transcription is a defining feature of active enhancers, linking transcription factor (TF) binding to the molecular mechanisms controlling gene expression. To determine the relationship between enhancer activity and biological outcomes in breast cancers, we profiled the transcriptomes (using GRO-seq and RNA-seq) and epigenomes (using ChIP-seq) of 11 different human breast cancer cell lines representing five major molecular subtypes of breast cancer, as well as two immortalized (“normal”) human breast cell lines. In addition, we developed a robust and unbiased computational pipeline that simultaneously identifies putative subtype-specific enhancers and their cognate TFs by integrating the magnitude of enhancer transcription, TF mRNA expression levels, TF motif P-values, and enrichment of H3K4me1 and H3K27ac. When applied across the 13 different cell lines noted above, the Total Functional Score of Enhancer Elements (TFSEE) identified key breast cancer subtype-specific TFs that act at transcribed enhancers to dictate gene expression patterns determining growth outcomes, including Forkhead TFs, FOSL1, and PLAG1. FOSL1, a Fos family TF, (1) is highly enriched at the enhancers of triple negative breast cancer (TNBC) cells, (2) acts as a key regulator of the proliferation and viability of TNBC cells, but not Luminal A cells, and (3) is associated with a poor prognosis in TNBC breast cancer patients. Taken together, our results validate our enhancer identification pipeline and reveal that enhancers transcribed in breast cancer cells direct critical gene regulatory networks that promote pathogenesis.

1 April 2015 in Molecular Cell
Verified
Journal Article
Closed access
HFHector L. Franco
Hector L. Franco
ANAnusha Nagari
Anusha Nagari
WKW. Lee Kraus
W. Lee Kraus

20 February 2018 in BMC Genomics
Verified
Journal Article
Open access
PDF file
YXYuanxin Xi
Yuanxin Xi
JSJiejun Shi
Jiejun Shi
WLWenqian Li
Wenqian Li
KTKaori Tanaka
Kaori Tanaka
KAKendra L. Allton
Kendra L. Allton
SDSharon Y. R. Dent
Sharon Y. R. Dent
Epigenetic regulators are frequently mutated or aberrantly expressed in a variety of cancers, leading to altered transcription states that result in changes in cell identity, behavior, and response to therapy. To define alterations in epigenetic landscapes in breast cancers, we profiled the distributions of 8 key histone modifications by ChIP-Seq, as well as primary (GRO-seq) and steady state (RNA-Seq) transcriptomes, across 13 distinct cell lines that represent 5 molecular subtypes of breast cancer and immortalized human mammary epithelial cells. Using combinatorial patterns of distinct histone modification signals, we defined subtype-specific chromatin signatures to nominate potential biomarkers. This approach identified AFAP1-AS1 as a triple negative breast cancer-specific gene associated with cell proliferation and epithelial-mesenchymal-transition. In addition, our chromatin mapping data in basal TNBC cell lines are consistent with gene expression patterns in TCGA that indicate decreased activity of the androgen receptor pathway but increased activity of the vitamin D biosynthesis pathway. Together, these datasets provide a comprehensive resource for histone modification profiles that define epigenetic landscapes and reveal key chromatin signatures in breast cancer cell line subtypes with potential to identify novel and actionable targets for treatment.

1 August 2010 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
TTTurgut Tukel
Turgut Tukel
DŠDražen Šošić
Dražen Šošić
LALihadh I. Al-Gazali
Lihadh I. Al-Gazali
MEMónica Erazo
Mónica Erazo
JCJose Casasnovas
Jose Casasnovas
RDRobert J. Desnick
Robert J. Desnick